Editors: Olga Pozdnyakova, MD, PhD, Geoffrey Wool, MD, PhD, David Bernard, MD, PhD & Raul S. Gonzalez, MD
Submit your pathology-related question for reply by appropriate medical consultants. CAP TODAY will make every effort to answer all relevant questions. However, those questions that are not of general interest may not receive a reply. For your question to be considered, you must include your name and address; this information will be omitted if your question is published in CAP TODAY. Submit a question.
Q. How has the National Comprehensive Cancer Network guideline approach to cytogenetic testing in multiple myeloma evolved, and why does this matter for patient care?
November 2026—A. Recent NCCN guideline updates for multiple myeloma have clarified and refined the role of cytogenetic testing, emphasizing methods that reliably evaluate the neoplastic plasma cell population.
Historically, karyotype analysis was often included in the initial workup. However, in NCCN version 1.2025, routine metaphase cytogenetic analysis is only recommended if there is suspicion for myelodysplasia. This change reflects the low sensitivity of karyotyping in myeloma due to poor plasma cell proliferation in culture. Despite its historical role in risk assessment, metaphase cytogenetics is no longer included among the recommended studies in the NCCN guidelines as of September 2026.
In NCCN v5.2026, FISH on CD138-enriched plasma cells was reaffirmed as a central component of diagnostic evaluation for multiple myeloma. FISH detects cytogenetic abnormalities that directly inform risk stratification, prognosis, and therapeutic decision-making.
Importantly, despite advances in next-generation sequencing technologies, cytogenetic testing remains an integral part of multiple myeloma diagnosis and patient management.
The updated NCCN guidelines promote precision testing, avoid low-yield studies, and ensure that cytogenetic results meaningfully inform patient care. The CAP Clinical Pathology Improvement Program case-based activity on cytogenetics testing of plasma cell neoplasms incorporates these updates and provides an opportunity for pathologists and, particularly, noncytogeneticists, to understand how cytogenetic testing should be applied in myeloma management.
The CPIP case-based activity (available for purchase at https://bit.ly/CAP_CPIP-FISH) provides further information about navigating cytogenetic testing. Additional CPIP online activities are available at https://education.cap.org/casebased.
Ina Diwata Amarillo, PhD, FACMG, ErCLG
Associate Professor
Director, Genomics Pathology Laboratory
Department of Pathology and Laboratory Medicine
Penn State College of Medicine
Hershey, Pa.
Member, CAP Clinical Pathology Education Committee
Hulya Keskin, MD
Postgraduate Year Four Pathology Resident
Penn State College of Medicine
Hershey, Pa.
Q. If you find smudge cells in a blood smear when performing a manual differential count and their morphological features allow you to classify those cells, do you categorize them as smudge cells or based on their distinct features? At what percentage of smudge cells is an albumin preparation performed?
A. The CAP’s Hematology and Clinical Microscopy Glossary notes that smudge, or basket, cells are “most commonly associated with cells that are fragile and easily damaged in the process of making a peripheral blood smear. The nucleus may either be a nondescript chromatin mass or the chromatin strands may spread out from a condensed nuclear remnant, giving the appearance of a basket. Cytoplasm is either absent or indistinct. Smudge cells are usually lymphocytes, but there is no recognizable cytoplasm to give a clue to the origin of the cell.”
Per International Council for Standardization in Haematology recommendations, when the nature of the smear cell is apparent, it should be counted as the cell from which it is derived rather than categorized as a smudge cell. In other words, if sufficient morphological features remain to identify the cell lineage (e.g. a smudged lymphocyte that is clearly lymphoid in origin), the cell should be classified accordingly and included in the WBC differential count. Only cells with unidentifiable disrupted nuclei should be categorized as smudge cells.
When large numbers of smudge cells are present (commonly seen in chronic lymphocytic leukemia), the ICSH recommends reporting the automated differential, if available, with a comment in the film report noting the presence of smudge cells.
As to the reader’s question about albumin preparation, the ICSH guidelines describe the albumin technique (one part albumin added to four parts blood) as a method to prevent cell disruption and identify fragile cells for inclusion in the differential. However, neither the ICSH nor Clinical and Laboratory Standards Institute defines a percentage threshold of smudge cells at which albumin preparation becomes mandatory. The recommendation is framed qualitatively: When “large numbers” of smudge cells are present and interfere with differential counting, a repeat albumin-enhanced film should be prepared.
Many laboratories establish their own internal threshold—about 20 to 25 percent smudge cells as a trigger—but this is institution specific rather than a universally standardized cutoff. The albumin technique has been validated using a 1:12 dilution of 22 percent bovine serum albumin, which significantly reduces smudge cells and improves morphologic assessment, particularly in chronic lymphocytic leukemia.
College of American Pathologists. Hematology and Clinical Microscopy Glossary. 2026. cap.org/wp-content/uploads/documents/2026-Heme-Glossary-FINAL.pdf
Lunning MA, Zenger VE, Dreyfuss R, et al. Albumin enhanced morphometric image analysis in CLL. Cytometry B Clin Cytom. 2004;57(1):7–14.
Palmer L, Briggs C, McFadden S, et al. ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features. Int J Lab Hematol. 2015;37(3):287–303.
Zini G. How I investigate difficult cells at the optical microscope. Int J Lab Hematol. 2021;43(3):346–353.
Olga Pozdnyakova, MD, PhD
Director, Division of Hematopathology
Professor, Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
Philadelphia, Pa.
Chair, CAP Hematology/Clinical Microscopy Committee